Upgrade to SI Premium - Free Trial

Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)

October 6, 2016 8:31 AM
Kite Pharma, Inc. (Nasdaq: KITE) announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles